Equillium

EQ

Market cap $86.9M

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates.

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

While last month ended up being a decent one for the Nasdaq Composite, it was downright fantastic for a handful of Nasdaq-listed names. Here's a rundown of the Nasdaq Composite's five-best performing stocks that blew the index's 1.6% August gain out of the water.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.

Equillium, Inc. secured up to $50 million in funding to advance EQ504, its novel AhR modulator, for ulcerative colitis treatment. A phase 1 proof-of-concept study for EQ504 in ulcerative colitis is set to begin in mid-2026, with early data expected within six months afterwards. EQ504's mechanism is validated by Tapinarof's approval in skin disorders, supporting its potential in both gastrointestinal and lung indications; Along with POC of anti-inflammatory cytokines IL-10 and IL-22.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront financing of approximately $30 million in gross proce.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #Bitcoin--Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced a strategic expansion to integrate a cryptocurrency treasury reserve strategy as part of its broader financial and growth objectives. “As we are actively evaluating strategic options for the company, I am pleased to announce we have expanded our treasury strategy to include digital currencies for the diversif.

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7. “Decades of independent research have validated Ah.

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor (AhR) modulator (EQ504), which was acquired through the acquisition of Ariagen, a biotechnology company that was majority owned by Equillium's largest investor, Decheng Capital. AhR.